论文部分内容阅读
目的:研究化疗患者发生骨髓抑制情况与抗肿瘤药之间相关关系。方法:回顾性调查了6 884例化疗住院患者,以时间为单位,将化疗患者骨髓抑制发生率和药物病例使用支持密度进行多元岭回归分析。结果:化疗患者骨髓抑制发生率与铂类药物、抗肿瘤抗生素、抗代谢药、植物抗微管药、烷化剂的病例使用支持密度呈多元岭回归关系。其回归系数分别为0.06,-0.065,0.131,0.014,0.231,3.067。结论:化疗人群中抗肿瘤药引起的骨髓抑制发生率,由强到弱的药物因素为烷化剂、抗代谢抗肿瘤药、金属络合物抗肿瘤药物、植物抗微管药和抗肿瘤抗生素。
Objective: To study the relationship between myelosuppression and anti-tumor drugs in chemotherapy patients. Methods: A retrospective survey of 6,884 patients with chemotherapy inpatients, the time as a unit, the incidence of bone marrow suppression in patients with chemotherapy and drug support using MDR regression analysis. Results: The incidence of bone marrow suppression in patients with chemotherapy and platinum drugs, anti-tumor antibiotics, anti-metabolites, plant anti-microtubule drugs, alkylating agent case support density was Ridge regression. The regression coefficients were 0.06, -0.065, 0.131, 0.014, 0.231, 3.067 respectively. Conclusion: The incidence of myelosuppression caused by anti-tumor drugs in chemotherapy population is from strong to weak drug factors to alkylating agents, antimetabolite anti-tumor drugs, metal complex anti-tumor drugs, plant anti-microtubule drugs and antitumor antibiotics .